60
Participants
Start Date
March 1, 2024
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
Avatrombopag
"After enrollment, all subjects receive Avatrombopag treatment. The initial dose of Avatrombopag administration was an oral 10 mg (\<30kg) or 20mg (≥30kg) once daily in all participants. ps. For subjects weighing ≥30kg, the dose can be started from 40mg once daily if the platelet count is \< 10×10\^9/L or if there is severe bleeding or risk of bleeding.~Complete blood count including platelet count was done once a week. The dose of Avatrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count was less than 30×10\^9/L for 2 weeks, avatrobopag was gradually increased. If the platelet count was greater than 150 x 10\^9/L, avatrobopag was gradually reduced. If the platelet count \>250×10\^9/L, avatrobopag will be stoped until the platelet count \<100×10\^9/L."
RECRUITING
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin
Henan Cancer Hospital
OTHER_GOV
Tianjin Medical University Second Hospital
OTHER
Tianjin Children's Hospital
OTHER
The Second Affiliated Hospital of Kunming Medical University
OTHER
Institute of Hematology & Blood Diseases Hospital, China
OTHER